CClinicalTrials.gg
TerminatedNCT02995603Nano-XUpdated May 19, 2026

Patient Experience and Acceptance of Horizontal Rotation

An interventional study of Nano-X patient rotation in Cancer, sponsored by University of Sydney. Terminated at 1 site in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-19.

Sponsored by University of Sydney · Not applicable, Interventional, and Basic science

Why this study was terminated
Ongoing funding ceased
Phase
Not applicable
Study type
Interventional
Enrollment
43
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

Patients will complete validated psychometric questionnaires to quantify their experience of being rotated at different speeds using the Nano-X patient rotation system.

Read the detailed description

Study participants will be asked to attend the clinic on two separate occasions. Each session will last less than one hour. Patients will be asked to complete validated psychometric surveys assessing 1) their level of claustrophobia, 2) their level of anxiety and 3) their (baseline) motion sickness, before and after each session. They will then be rotated 3-4 times on the Nano-X patient rotation system, at varying speeds ranging from 6°/sec to 45°/sec. Each rotation will be designed to simulate a typical radiotherapy treatment; that is 9 angles, pausing for around 30 seconds at each angle. Straight after each rotation, patients will again complete the questionnaire assessing their anxiety levels and motion sickness.

02

Conditions studied

  • Cancer

Browse trials for

Keywords

  • Radiotherapy
  • Rotation
03

In context

Neoplasms

9,365 studies on the registry are indexed under Neoplasms; 2,489 are open to participants now.

This study's enrollment of 43 is below the median of 50 across 7,253 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

University of Sydney is the lead sponsor of 91 studies on the registry; 25 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. A diagnosis of cancer, any stage
  2. ≥18 years of age
  3. Eastern Cooperative Oncology Group (ECOG) status 0-2
  4. Currently or previously being treated with radiotherapy
  5. Any prior therapy allowed
  6. Willing and able to comply with all study requirements
  7. Must be able to read and complete questionnaires in English
  8. Signed, written informed consent

Exclusion criteria

Exclusion Criteria:

  1. Pregnant women
  2. Mentally impaired patients or patients for whom attaining informed consent would be difficult (including language barriers)
  3. Severe vertigo or recent diagnosis of Benign Paroxysmal Positioning Vertigo
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
43 participants (actual)

Study arms

  • Experimental
    Patient rotation

    Patients will be rotated horizontally, using the Nano-X patient rotation system, and asked to complete validated questionnaires to quantify their experience.

    Device: Nano-X patient rotation

Interventions

  • DeviceNano-X patient rotation

    Patients are required to completed validated questionnaires to quantify their experience of horizontal rotation.

06

What researchers measure

Primary outcomes

  1. Change in level of patient anxiety following rotation in the Nano-X Patient Rotation System

    Comparison of mean scores of Short Form State/Trait Anxiety Inventory (STAI) Questionnaire outcomes before and after being rotated in the Nano-X Patient Rotation System

    Time frame: 1 hour

  2. Change in level of patient motion sickness following rotation in the Nano-X Patient Rotation System

    Comparison of mean scores of Fast Motion Sickness Test (FMS) Questionnaire outcomes before and after being rotated in the Nano-X Patient Rotation

    Time frame: 1 hour

  3. Correlation between claustrophobia and the change in anxiety and motion sickness of patients following rotation in the Nano-X Patient Rotation System

    Correlation between Claustrophobia Questionnaire (CLQ) scores prior to study participation on the anxiety and motion sickness results measured in Outcome 1 and Outcome 2

    Time frame: 1 year

07

Study locations

1 site
  • Prince of Wales Hospital
    Randwick, New South Wales 2031, Australia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02995603
Lead sponsor
University of Sydney
Collaborators
Prince of Wales Hospital, Sydney
Responsible party
Sponsor
First posted
Dec 16, 2016
Start date
Dec 14, 2019
Primary completion
Dec 31, 2025
Completion
Dec 31, 2025
Last update
May 19, 2026

Study contacts

Paul Keall, Prof
study chair · University of Sydney

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion